文献速递瓣膜外科

生物瓣尺寸对初次主动脉瓣置换术长期预后的影响

Prognostic influence of biological valve size on long-term outcomes of primary surgical aortic valve replacement for aortic stenosis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-09-29

本研究回顾754例因主动脉瓣狭窄行初次生物瓣主动脉瓣置换术的患者,按瓣膜尺寸分为19mm、21mm和≥23mm三组。

要点

  • 19mm生物瓣术后严重PPM发生率15%,高于21mm的5.8%和≥23mm的5.0%。

核心结论

  • 尽管19mm生物瓣术后严重PPM和主动脉再干预发生率更高,但对体表面积小的老年患者仍可合理使用,因长期生存和左心室质量回归与较大瓣膜等效。

研究设计与样本

  • 回顾性队列研究,纳入754例因主动脉瓣狭窄行初次生物瓣SAVR的连续患者,按瓣膜尺寸分为19mm(n=246)、21mm(n=262)和≥23mm(n=246)三组,平均观察6.6±4.0年(4996患者年)。

主要发现

  • 19mm组患者更年长(74±7.8岁 vs 72±8.0岁 vs 69±10岁),女性比例更高(91% vs 55% vs 13%),体表面积更小(1.39±0.12 m2 vs 1.53±0.15 m2 vs 1.67±0.16 m2)。
  • 混合效应模型显示左心室质量指数回归等效(交互效应=0.189)。
  • 随访期间共142例(19%)死亡和41例(5.4%)主动脉瓣再干预(31例再次SAVR和10例瓣中瓣)。

关键数值与推荐

  • 严重PPM定义:体重指数<30 kg/m2时 indexed effective orifice area ≤0.65 cm2/m2,体重指数≥30 kg/m2时≤0.55 cm2/m2。

临床怎么用

  • 对于体表面积小的老年主动脉瓣狭窄患者,选用19mm生物瓣可接受,但需告知再干预风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We clarified associations between biological valve sizes selected during primary surgical aortic valve replacement (SAVR) and its long-term outcomes. METHODS: In total, 754 consecutive patients with aortic stenosis who underwent primary biological SAVR were classified into 3 groups based on valve size: 19-mm (n = 246), 21-mm (n = 262), and ≥23-mm (n = 246). Severe prosthesis-patient mismatch was defined as measured indexed effective orifice area ≤0.65 cm2/m2 if body mass index is < 30 kg/m2 and ≤ 0.55 cm2/m2 if body mass index is ≥ 30 kg/m2. The mean observation period was 6.6 ± 4.0 years (4996 patient-years). RESULTS: Patients with 19-mm valves were older (19-mm: 74 ± 7.8 years vs 21-mm: 72 ± 8.0 years vs ≥ 23-mm: 69 ± 10 years), predominantly women (91% vs 55% vs 13%), and had smaller body surface area (1.39 ± 0.12 m2 vs 1.53 ± 0.15 m2 vs 1.67 ± 0.16 m2). The incidence of post-SAVR severe prosthesis-patient mismatch was 15%, 5.8%, and 5.0%, respectively (P < .001 for all). However, a mixed-effects model demonstrated that left ventricular mass index regressed equivalently (interaction effect = 0.189). During follow-up, 142 (19%) mortalities and 41 (5.4%) aortic valve reinterventions (31 redo-SAVR and 10 valve-in-valve) were observed, without difference in 10-year all-cause mortality rate (21% vs 33% vs 27%; P = .438). Fine-Gray regression model identified age at surgery (adjusted hazard ratio, 0.4 per 10-years; P < .001) and use of a 19-mm valve (adjusted hazard ratio, 4.0; P < .001) as independent associates with aortic valve reinterventions. CONCLUSIONS: Despite a higher incidence of severe prosthesis-patient mismatch and aortic reintervention after primary SAVR, use of a 19-mm biological valve can be justified for elderly patients with small body surface area, as evidenced by equivalent long-term survival and left ventricular mass regression to those with larger valves.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kutsuzawa R, Kainuma S, Kawamoto N, et al. Prognostic influence of biological valve size on long-term outcomes of primary surgical aortic valve replacement for aortic stenosis. J Thorac Cardiovasc Surg. 2025. PMID: 41033648. doi:10.1016/j.jtcvs.2025.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。